Literature DB >> 31612630

Intradialytic exercise with blood flow restriction: Something to add to hemodialysis adequacy? Findings from a crossover study.

Etiene C Dias1, Rafael Orcy2, Maria F Antunes1, Rodrigo Kohn3, Airton J Rombaldi3, Larissa Ribeiro1,4, Jean P Oses1, Gustavo D Ferreira2, Aline M Araújo3, Isis F Boff1, Maristela Böhlke1,4.   

Abstract

INTRODUCTION: Hemodialysis (HD) increases the lifespan of chronic kidney disease (CKD) patients. However, HD is only partially effective in replacing renal function. The aim of this study is to compare HD adequacy between sessions with intradialytic exercise with or without blood flow restriction (BFR) with sessions without exercise.
METHODS: A crossover study including 22 adult CKD patients on HD. The patients were assigned to BFR (n = 11) or exercise alone group (n = 11). Each patient was submitted to four HD sessions (two with exercise and two control sessions). HD adequacy was assessed by equilibrated Kt/V-urea (eKT/V), single-pool Kt/V-urea (sp-Kt/V), urea and phosphorus rebound, urea reduction ratio (URR) and removal of urea and phosphorus in dialysate.
FINDINGS: BFR exercise improved eKt/V and sp-Kt/V (1.32 ± 0.21 vs. 1.10 ± 0.16 for control, P < 0.001; 1.53 ± 0.26 vs. 1.27 ± 0.19 for control, P < 0.001, respectively) and URR (72.5 ± 5.4% vs. 66.1 ± 7.7% for control, P < 0.001). No difference in eKt/V, sp-Kt/V or URR could be detected between exercise alone and control HD sessions. Urea rebound was lower in BFR exercise vs. control sessions (-8.9 ± 9.1% vs. 30.7 ± 12.8%, P < 0.01) and exercise alone vs. control sessions (13.3 ± 29.0% vs. 42.4 ± 15.3%, P < 0.01). Phosphorus rebound was marginally lower in exercise vs. control sessions (14.4 ± 19.1% vs. 28.4 ± 22.1%, P = 0.18). Urea and phosphorus mass removal in dialysate were marginally higher in exercise vs. control sessions (42.2 ± 19.4 g vs. 35.7 ± 12.5 g, P = 0.24; 912.1 ± 360.9 mg vs. 778.6 ± 245.1 mg, P = 0.28).
CONCLUSIONS: Intradialytic exercise with BFR was more effective than standard exercise in increasing HD adequacy.
© 2019 International Society for Hemodialysis.

Entities:  

Keywords:  adequacy of dialysis; blood flow restriction; exercise; technical hemodialysis

Year:  2019        PMID: 31612630     DOI: 10.1111/hdi.12793

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  5 in total

1.  The effect of a 6-month intradialytic exercise program on hemodialysis adequacy and body composition: a randomized controlled trial.

Authors:  Ekaterini Vogiatzaki; Vassiliki Michou; Vassilios Liakopoulos; Athanasios Roumeliotis; Stefanos Roumeliotis; Evangelia Kouidi; Asterios Deligiannis
Journal:  Int Urol Nephrol       Date:  2022-05-23       Impact factor: 2.266

Review 2.  Exercise training for adults undergoing maintenance dialysis.

Authors:  Amelie Bernier-Jean; Nadim A Beruni; Nicola P Bondonno; Gabrielle Williams; Armando Teixeira-Pinto; Jonathan C Craig; Germaine Wong
Journal:  Cochrane Database Syst Rev       Date:  2022-01-12

Review 3.  Potential implications of blood flow restriction exercise on patients with chronic kidney disease: a brief review.

Authors:  Nicholas Rolnick; Ivo Vieira de Sousa Neto; Eduardo Fernandes da Fonseca; Rodrigo Vanerson Passos Neves; Thiago Dos Santos Rosa; Dahan da Cunha Nascimento
Journal:  J Exerc Rehabil       Date:  2022-04-26

Review 4.  A Useful Blood Flow Restriction Training Risk Stratification for Exercise and Rehabilitation.

Authors:  Dahan da Cunha Nascimento; Nicholas Rolnick; Ivo Vieira de Sousa Neto; Richard Severin; Fabiani Lage Rodrigues Beal
Journal:  Front Physiol       Date:  2022-03-11       Impact factor: 4.566

Review 5.  Intradialytic Nutrition and Hemodialysis Prescriptions: A Personalized Stepwise Approach.

Authors:  Giorgina Barbara Piccoli; Francoise Lippi; Antioco Fois; Lurlynis Gendrot; Louise Nielsen; Jerome Vigreux; Antoine Chatrenet; Claudia D'Alessandro; Gianfranca Cabiddu; Adamasco Cupisti
Journal:  Nutrients       Date:  2020-03-16       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.